reports
- Jacob Mekhael
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
UCB Publishes Fintepla LGS open-label extension results in journal
UCB announced that the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in the Epilepsy and Behavior journal. This follows previous presentations at a medical conference and highlights the long-term sustained benefit and lack of new or unexpected safety signals, which we view as supportive of Fintepla's benefit in this patient population. For reference, Fintepla is one of UCB's 5 growth drivers, and we estimate peak s...
- Jacob Mekhael
UCB Publishes pyrimidine nucleo(s)(t)ide therapy results in TK2d in jo...
UCB announced the publication of results from a multicenter retrospective chart review study of pyrimidine nucleo(s)(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) in Neurology, which are in line with previous reports of the positive outcomes on survival and functional outcomes presented at a medical conference earlier this year. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 per 1m people. Doxecitine an...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
Corbion reports the progress of its share buyback program 6 October – ...
Corbion reports the progress of its share buyback program 6 October – 10 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 6 October up to and including 10 October 2025 a total of 35.578 shares were repurchased at an average price of €16.7661 for a total amount of €596,504.09 To date, the total consideration for shares repurchased amounts to €4,525,155.64 representing 45.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of ...
- ING Helpdesk
Benelux Morning Notes
Ageas: AG Real Estate looking to reduce exposure to Interparking, lower capital charges. Air France-KLM: 3Q25 a bit light? ASML: Preview 3Q25, riding the AI wave. Barco: Preview 3Q25, self-help offsets macro headwind. D'Ieteren: Belron starts to roll out static mobile recalibration. Euronext: September's seasonal recovery. Tessenderlo More focus on capital allocation and returns. TomTom: Preview 3Q25, Cost cutting offsets slow markets. Umicore: Gold inventory sale-and-lease-back
- Kristof Samoy
- Wim Hoste
UCB SA: 2 directors
Two Directors at UCB SA sold after exercising options/sold 8,000 shares at between 248.275EUR and 252.680EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...
Corbion reports the progress of its share buyback program 29 September...
Corbion reports the progress of its share buyback program 29 September – 3 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 29 September up to and including 03 October 2025 a total of 22.839 shares were repurchased at an average price of €16.514 for a total amount of €377,157.94 To date, the total consideration for shares repurchased amounts to €3,928,651.07 representing 39.29% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress...
- Ahmed Ben Salem
VAC PIERRE & VACANCES SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BON BONDUELLE SCA
NANO NANOBIOTIX SA
CFEB COMPAGNIE D'ENTREPRISES CFE SA
SIGHT GENSIGHT BIOLOGICS SA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
DGM DIAGNOSTIC MEDICAL SYSTEMS
SPIE SPIE SA
HOME NEINOR HOMES SA
WAGA WAGA ENERGY SA
CTPNV CTP NV
LHYFE LHYFE S.A.
ORP ORPEA
4X0 STEYR MOTORS AG
HAVAS HAVAS N.V
- Ahmed Ben Salem
VAC PIERRE & VACANCES SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BON BONDUELLE SCA
NANO NANOBIOTIX SA
CFEB COMPAGNIE D'ENTREPRISES CFE SA
SIGHT GENSIGHT BIOLOGICS SA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
DGM DIAGNOSTIC MEDICAL SYSTEMS
SPIE SPIE SA
HOME NEINOR HOMES SA
WAGA WAGA ENERGY SA
LHYFE LHYFE S.A.
ORP ORPEA
4X0 STEYR MOTORS AG
HAVAS HAVAS N.V
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
- Jacob Mekhael
UCB Galvokimig R&D call highlights potential in AD, model update
Yesterday, UCB hosted an R&D call to highlight the phase 2a data for galvokimig from EADV 2025, which showed strong efficacy in atopic dermatitis (AD), with a 52.6% placebo-adjusted EASI75 response at week 12, outperforming other biologics in cross-trial comparison. The KOL highlighted galvokimig's potential for broad positioning across the AD treatment paradigm if the early data is replicated in later stage trials, especially as a monotherapy. We update our model for UCB, which brings us to a n...
- Thijs Berkelder
- Baptiste Salaville
- Bruno Cavalier
- Konrad Zomer
SU SCHNEIDER ELECTRIC SE
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ABB ABB LTD.
EL ESSILORLUXOTTICA SA
WKL WOLTERS KLUWER NV
BRBY BURBERRY GROUP PLC
KER KERING SA
BAS BASF SE
UCB UCB S.A.
01913 PRADA S.P.A.
MONC MONCLER SPA
YPSN YPSOMED HOLDING AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
PUIG PUIG BRANDS
- Baptiste Salaville
- Bruno Cavalier
- Konrad Zomer
SU SCHNEIDER ELECTRIC SE
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ABB ABB LTD.
EL ESSILORLUXOTTICA SA
WKL WOLTERS KLUWER NV
BRBY BURBERRY GROUP PLC
KER KERING SA
BAS BASF SE
UCB UCB S.A.
01913 PRADA S.P.A.
MONC MONCLER SPA
YPSN YPSOMED HOLDING AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
PUIG PUIG BRANDS
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
UCB Bimzelx competitor sonelokimab shows mixed phase 3 results in HS
In UCB related news, MoonLake Therapeutics (no coverage) reported topline phase 3 data for Bimzelx competitor, sonelokimab (IL-17A/F nanobody) in hidradenitis suppurativa (HS) that showed mixed results. Averaging both VELA-1 and VELA-2 trials brings us to a 13.5% placebo adjusted HiSCR75 response, which is lower than the 17.5% that Bimzelx showed in BE HEARD I and II, and the approx. 20% delta bar set by MoonLake's management earlier this year. Acknowledging the high placebo response in VELA-2, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.